

Literatur für onkologie heute 12/2020

SCHWERPUNKT: OVARIALKARZINOM

Therapie des Ovarialkarzinoms in der Rezidivsituation (S. 28–36)

C. Claussen, A. Rody, L. Hanker

1. Torre LA, Trabert B, DeSantis CE et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin* 2018; 68(4): 284 – 296
2. Wilson MK, Pujade-Lauraine E, Aoki D et al. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease. *Ann Oncol* 2017; 28(4): 727 – 732
3. du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer* 2009; 115(6): 1234– 1244
4. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003; 361(9375): 2099-2106
5. Colombo N, Sessa C, Bois A Du et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *Int J Gynecol Cancer* 2019; 29(4): 728 – 760
6. McGee J, Bookman M, Harter P et al. Fifth ovarian cancer consensus conference: Individualized therapy and patient factors. *Ann Oncol* 2017; 28(4): 702– 710
7. Friedlander ML. Do all patients with recurrent ovarian cancer need systemic therapy? *Cancer* 2019;125(S24): 4602 – 4608
8. Harter P, Sehouli J, Reuss A et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. *Int J Gynecol Cancer* 2011; 21(2): 289– 295
9. Harter P, Beutel B, Alesina PF et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. *Gynecol Oncol* 2014; 132(3): 537–541
10. Al Rawahi T, Lopes AD, Bristow RE et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. *Cochrane Database Syst Rev* 2013.
11. Du Bois A, Sehouli J, Vergote I et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. *J Clin Oncol* 2020; 38: 6000
12. Coleman RL, Spirtos NM, Enserro D et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. *N Engl J Med* 2019; 381(20): 1929– 1939
13. Grunewald T, Tang M, Chen J et al. Where have we gone wrong? Phase II trials (Ph2t) do not inform the results of phase III trials (Ph3t) in platinum resistant ovarian cancer (PROC). *J Clin Oncol* 2016; 34: 5559 – 5559
14. Roncolato FT, Berton-Rigaud D, O’Connell R et al. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). *Gynecol Oncol* 2018;148(1): 36 – 41
15. Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. *Ann Oncol* 2012; 23(10): 2605 – 2612

16. Friedlander ML, Stockler M, O'Connell R et al. Symptom Burden and Outcomes of Patients With Platinum Resistant/Refractory Recurrent Ovarian Cancer: A Reality Check. *Int J Gynecol Cancer* 2014; 24(5): 857 – 864
17. Corrado G, Salutati V, Palluzzi E et al. Optimizing treatment in recurrent epithelial ovarian cancer. *Expert Rev Anticancer Ther* 2017; 17(12): 1147 –1158
18. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. *J Clin Oncol* 2007; 25(19): 2811– 2818
19. Markman M, Blessing J, Rubin SC et al. Phase II trial of weekly paclitaxel (80 mg/m²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. *Gynecol Oncol* 2006; 101(3): 436 – 440
20. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A gynecologic oncology group study. *J Clin Oncol* 1998; 16(2): 405–410
21. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol* 2001; 19(14): 3312–3322
22. Coleman RL, Brady W, McMeekin DS et al. A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study. *J Clin Oncol* 2010; 28: 5010–5010
23. Safra T, Borgato L, Nicoletto MO et al. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. *Mol Cancer Ther* 2011; 10(10): 2000–2007
24. Colombo N, Gadducci A, Sehouli J et al. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. *Ann Oncol* 2020
25. Pujade-Lauraine. Errata: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial (*J Clin Oncol* 32:1302-1308, 2014). *J Clin Oncol* 2014; 32(35): 4025
26. Eisenhauer EA, Vermorken JB, Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. *Ann Oncol* 1997; 8(10): 963–968
27. Pignata S, Scambia G, Bologna A et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIg study. *J Clin Oncol* 2017; 35(29): 3347–3353
28. Pfisterer J, Dean AP, Baumann K et al. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab (CD-BEV) Carboplatin / Gemcitabine / Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. *Ann Oncol* 2018; 29: 332–258
29. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011; 365(26): 2473–2483
30. Norquist BM, Brady MF, Harrell MI et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. *J Clin Oncol* 2017; 139(1): JCO.19.01009
31. Coleman RL, Enserro D, Spirtos N et al. A phase iii randomized controlled trial of secondary cytoreductive surgery (SCS) followed by platinum-based chemotherapy (PC) platinum-sensitive, recurrent ovarian cancer (PSOC)-surgical parameters. *Int J Gynecol Cancer* 2018; 28: 52

32. Pignata S, Lorusso D, Joly F et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. *J Clin Oncol* 2018; 36: 5506–5506
33. Harter P, Hauke J, Heitz F et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). Galli A, ed. *PLoS One* 2017; 12(10): e0186043
34. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011; 474(7353): 609–615
35. Incorvaia L, Passiglia F, Rizzo S et al. “Back to a false normality”: New intriguing mechanisms of resistance to PARP inhibitors. *Oncotarget* 2017
36. Kristeleit RS, Miller RE, Kohn EC. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency. *Am Soc Clin Oncol Educ B* 2016
37. Richters LK, Schouten PC, Kommoss S et al. BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial. *J Clin Oncol* 2017; 35: 5546
38. Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: An updated systematic review with meta-analysis. *Oncotarget* 2017; 8(1): 285–302
39. Konstantinopoulos. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. *J Clin Oncol*. 2010; 28(32): 4868
40. Pujade-Lauraine E, Ledermann JA, Selle F et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017; 18(9): 1274–1284
41. Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. *Ther Adv Med Oncol* 2019; 11
42. Poveda A, Floquet A, Ledermann JA et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. *J Clin Oncol* 2020; 38: 6002–6002
43. Domchek SM, Aghajanian C, Shapira-Frommer R et al. Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. *Gynecol Oncol* 2016; 140(2): 199–203
44. Penson RT, Villalobos Valencia R, Cibula D et al. Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial. *J Clin Oncol* 2019; 37: 5506–5506
45. Mirza MR, Monk BJ, Herrstedt J et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med* 2016; 375(22): 2154–2164
46. Moore KN, Secord AA, Geller MA et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol* 2019; 20(5): 636–648
47. Swisher EM, Lin KK, Oza AM et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. *Lancet Oncol* 2017; 18(1): 75–87
48. Kristeleit RS, Shapira-Frommer R, Oaknin A et al. Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2). *Ann Oncol* 2016; 27: 296

49. Coleman RL, Oza AM, Lorusso D et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 390(10106): 1949–1961
50. Yokoyama Y. Recurrent epithelial ovarian cancer and hormone therapy. *World J Clin Cases* 2013; 1(6):187
51. Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report. *Gynecol Oncol* 1996; 62(1): 4–6
52. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. *Expert Rev Anticancer Ther* 2006; 6(1): 43–47
53. Papadimitriou CA, Markaki S, Siapkarakas J et al. Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer. *Oncology*. 2004; 66(2): 112 –117
54. Carmen MG de., Fuller AF, Matulonis U et al. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. *Gynecol Oncol* 2003; 91(3): 596–602
55. Ramirez PT, Schmeler KM, Milam MR et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. *Gynecol Oncol* 2008; 110(1): 56–59
56. Moore KN, Bookman M, Sehouli J et al. LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). *Ann Oncol* 2020
57. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science (80-)*. 2017; 357(6349): 409–413
58. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. *Clin Cancer Res* 2019; 25(13): 3753–3758
59. Hartkopf AD, Müller V, Wöckel A et al. Translational Highlights in Breast and Ovarian Cancer 2019-Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. *Geburtshilfe Frauenheilkd* 2019
60. Pujade-Lauraine E, Fujiwara K, Ledermann JA et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. *Gynecol Oncol* 2019; 154: 21–22